N-Acetylcysteine to Combat COVID-19: An Evidence Review
Zhongcheng Shi,1,2 Carlos A Puyo3 1Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; 2Department of Pathology, Texas Children’s Hospital, Houston, TX, USA; 3Department of Anesthesia and Critical Care, Holy Family Hospital, Steward Health Care, Methuen, M...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-11-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/n-acetylcysteine-to-combat-covid-19-an-evidence-review-peer-reviewed-article-TCRM |
| _version_ | 1831632053394735104 |
|---|---|
| author | Shi Z Puyo CA |
| author_facet | Shi Z Puyo CA |
| author_sort | Shi Z |
| collection | DOAJ |
| description | Zhongcheng Shi,1,2 Carlos A Puyo3 1Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; 2Department of Pathology, Texas Children’s Hospital, Houston, TX, USA; 3Department of Anesthesia and Critical Care, Holy Family Hospital, Steward Health Care, Methuen, MA, USACorrespondence: Zhongcheng Shi Tel +1- 832-824-0814Email zhongchs@bcm.eduAbstract: The novel coronavirus disease (COVID-19) is caused by a virus (SARS-Cov-2) and is known for inducing multisystem organ dysfunction associated with significant morbidity and mortality. Current therapeutic strategies for COVID-19 have failed to effectively reduce mortality rate, especially for elderly patients. A newly developed vaccine against SARS-Cov-2 has been reported to induce the production of neutralizing antibodies in young volunteers. However, the vaccine has shown limited benefit in the elderly, suggesting an age-dependent immune response. As a result, exploring new applications of existing medications could potentially provide valuable treatments for COVID-19. N-acetylcysteine (NAC) has been used in clinical practice to treat critically ill septic patients, and more recently for COVID-19 patients. NAC has antioxidant, anti-inflammatory and immune-modulating characteristics that may prove beneficial in the treatment and prevention of SARS-Cov-2. This review offers a thorough analysis of NAC and discusses its potential use for treatment of COVID-19.Keywords: N-acetylcysteine, SARS-Cov-2, COVID-19 |
| first_indexed | 2024-12-19T05:12:28Z |
| format | Article |
| id | doaj.art-7462d7358ee64346ab9b8d5838d7d199 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-19T05:12:28Z |
| publishDate | 2020-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-7462d7358ee64346ab9b8d5838d7d1992022-12-21T20:34:47ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2020-11-01Volume 161047105558833N-Acetylcysteine to Combat COVID-19: An Evidence ReviewShi ZPuyo CAZhongcheng Shi,1,2 Carlos A Puyo3 1Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; 2Department of Pathology, Texas Children’s Hospital, Houston, TX, USA; 3Department of Anesthesia and Critical Care, Holy Family Hospital, Steward Health Care, Methuen, MA, USACorrespondence: Zhongcheng Shi Tel +1- 832-824-0814Email zhongchs@bcm.eduAbstract: The novel coronavirus disease (COVID-19) is caused by a virus (SARS-Cov-2) and is known for inducing multisystem organ dysfunction associated with significant morbidity and mortality. Current therapeutic strategies for COVID-19 have failed to effectively reduce mortality rate, especially for elderly patients. A newly developed vaccine against SARS-Cov-2 has been reported to induce the production of neutralizing antibodies in young volunteers. However, the vaccine has shown limited benefit in the elderly, suggesting an age-dependent immune response. As a result, exploring new applications of existing medications could potentially provide valuable treatments for COVID-19. N-acetylcysteine (NAC) has been used in clinical practice to treat critically ill septic patients, and more recently for COVID-19 patients. NAC has antioxidant, anti-inflammatory and immune-modulating characteristics that may prove beneficial in the treatment and prevention of SARS-Cov-2. This review offers a thorough analysis of NAC and discusses its potential use for treatment of COVID-19.Keywords: N-acetylcysteine, SARS-Cov-2, COVID-19https://www.dovepress.com/n-acetylcysteine-to-combat-covid-19-an-evidence-review-peer-reviewed-article-TCRMn-acetylcysteinesars-cov-2covid-19 |
| spellingShingle | Shi Z Puyo CA N-Acetylcysteine to Combat COVID-19: An Evidence Review Therapeutics and Clinical Risk Management n-acetylcysteine sars-cov-2 covid-19 |
| title | N-Acetylcysteine to Combat COVID-19: An Evidence Review |
| title_full | N-Acetylcysteine to Combat COVID-19: An Evidence Review |
| title_fullStr | N-Acetylcysteine to Combat COVID-19: An Evidence Review |
| title_full_unstemmed | N-Acetylcysteine to Combat COVID-19: An Evidence Review |
| title_short | N-Acetylcysteine to Combat COVID-19: An Evidence Review |
| title_sort | n acetylcysteine to combat covid 19 an evidence review |
| topic | n-acetylcysteine sars-cov-2 covid-19 |
| url | https://www.dovepress.com/n-acetylcysteine-to-combat-covid-19-an-evidence-review-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT shiz nacetylcysteinetocombatcovid19anevidencereview AT puyoca nacetylcysteinetocombatcovid19anevidencereview |